Company Interview / The small-cap making big strides in ALS treatment

Key points:

Dr Michael Thurn highlights recent breakthroughs in ALS treatment by Neurizon Therapeutics (ASX:NUZ)Neurizon achieves orphan product designation in Europe and progresses with FDA filingsPlans to extend treatment research to diseases like Alzheimer's are underway

Dr Michael Thurn from Neurizon Therapeutics (ASX:NUZ) shares significant developments in their neurodegenerative treatments. Over the week, Neurizon reports a decrease in the mortality risk for ALS patients by about 80%, following 27 months of treatment.

Michael notes the approval of orphan medicinal product designation in Europe, granting 10 years of market exclusivity if future approval is secured. Furthermore, Neurizon files its investigational new drug application with the FDA, opening doors for US clinical trials.

Michael emphasises the importance of these milestones for ALS patients reliant on limited existing treatments. He acknowledges the robust 60% stock rise and outlines potential expansions into treatments for diseases like Alzheimer's. Neurizon's ongoing commitment to innovation is evident in its rebranding efforts.